Please login to the form below

Not currently logged in

Eisai and SFJ Pharma form partnership

Eisai has agreed a partnership with US-based SFJ Pharma in a bid to speed up development of its pipeline

Eisai has entered into a collaborative development agreement with SFJ Pharma, a wholly-owned subsidiary of SFJ Pharmaceuticals, in an effort to further accelerate the late-stage clinical development of its pipeline.

Eisai said the deal will effectively leverage internal resources, as well as build a new partnership scheme. Under the scheme, Eisai will accept funding from external parties to conduct phase III studies for promising new drug candidates in order to push forward with numerous development programmes simultaneously and as quickly as possible.

The Japanese pharmaceutical company has entered into a collaborative development agreement with SFJ to conduct phase III studies with E7080 (lenvatinib) in thyroid cancer. These late-stage studies will be conducted by Eisai and wholly funded by SFJ, with Eisai paying SFJ milestone payments if E7080 obtains regulatory approval. If the compound is approved, all commercial rights shall remain with Eisai.

Eisai has previously established a strategic collaboration with Quintiles, through which it has been advancing multiple candidate anticancer compounds for proof of concept studies.

7th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...